Navigation Links
Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
Date:9/7/2011

enta Therapeutics and Reed Smith LLP served as its legal counsel.

For additional information on Ascenta Therapeutics, please visit the company's website at http://www.ascenta.com.

Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax:  +41(0)21-321-01-69
mwagner@debiopharm.com

Ascenta Therapeutics Contact
Brian Wood
Director, Corporate Development
Tel:  +1-610-725-1505
Fax: +1-610-408-0321
bwood@ascenta.com

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Lena Evans
Account Executive
Tel:  +1-212-845-4262
Fax: +1-212-845-4260
lena.evans@russopartnersllc.com


 



'/>"/>
SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Whitehouse Laboratories is excited to ... with PTI Inspection Systems that will enable ... the art leak testing method development and validation programs ... available. As part of this agreement, Whitehouse Labs has ... Detection Instrument developed and manufactured by PTI. The ...
(Date:8/27/2014)... 27, 2014 Rhythm, a biopharmaceutical company developing ... that result in metabolic disorders, announced today that it ... the U.S. Securities and Exchange Commission (SEC) relating to ... common stock. The number of shares to be offered ... yet been determined. Citigroup and Cowen and ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Chelating Agents Market 2014-2018 ... Chelating Agent A chelating agent is a chemical ... ions, thereby forming a metal-ion complex. It reduces ... chemical processes, formulations, and the environment by chelating ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4
... Virtify, Inc., a leading provider of structured content ... the appointment of Craig Smith as the company,s new ... the enterprise software industry, Smith has established a strong ... new markets and building outstanding sales organizations. ...
... Neuralstem, Inc. (Amex: CUR ) announced ... ending litigation between the parties.  The confidential settlement agreement ... Neuralstem, Inc. v. ReNeuron, Ltd. , Case No. ... United States District Court for the Central District of ...
... WASHINGTON, Jan. 27, 2011 Following are the comments ... (D-Ore.) on USDA,s announcement Thursday that the agency will ... engineered (GE) alfalfa, a key commodity in dairy farming, ... GE crop approved for widespread planting. Leahy and DeFazio ...
Cached Biology Technology:Content Management and Life Sciences Software Veteran Joins Virtify as Vice President of Worldwide Sales 2Content Management and Life Sciences Software Veteran Joins Virtify as Vice President of Worldwide Sales 3Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd. 2USDA's Decision Thursday on Genetically Engineered Alfalfa -- Leahy and DeFazio Warn About USDA Decision Lifting All Protections for Organic and Conventional Farmers 2
(Date:8/28/2014)... 2014  Privacy Advocate and Senior Staff Attorney at ... joins the lineup of biometric and mobile commerce experts ... Executive Summit in Tampa, Florida ... speakers include Steven Rahman, Director, Technology and Strategy at Samsung, ... The theme of this year,s event is Mobility at ...
(Date:8/28/2014)... 28, 2014A new method for measuring and imaging how ... and researchers better understand how drug abuse affects the ... tissue engineering, and lead to better treatment options for ... team of researchers from Stony Brook University in New ... was published today in The Optical Society,s (OSA) open-access ...
(Date:8/28/2014)... could pose a significant health risk to people with asthma ... of Allergy and Clinical Immunology . , By critically reviewing ... research has found that the presence of several types of ... well as increasing the likelihood of developing the condition. , ... University of Exeter Medical School and is the first time ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Indoor mold poses health risk to asthma sufferers 2
... the open state of a membrane-protein's ion channel have ... to obtain a detailed picture of the effect of ... residues for protons. , The findings, reported in the ... welcome news for chemists and biophysicists, both experimentalists and ...
... Researchers at the Oregon National Primate Research Center at ... key gene that appears to control how stem cells ... significant implications for the study of Parkinson's disease, brain ... that might be combated by replacing lost or damaged ...
... Department of Chemistry have developed a gel that could ... side-effects of radiotherapy. , PhD students Andrew Wilson and ... have developed the gel which will help doctors to ... has secured £30,000 under the Bioscience Yorkshire Enterprise Fellowship ...
Cached Biology News:New technique helps researchers determine amino-acid charge 2OHSU discovery sheds light into how stem cells become brain cells 2Young scientists turn to gel to ease side-effects of cancer treatment 2
1 unit is sufficient for 1 caspase activity assay....
Applications: (+) Immunocytochemistry and immunohistochemistry...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: